This scoping review found that chemotherapy-induced alopecia in breast cancer patients, especially when using anthracycline- and taxane-based regimens, occurs at higher rates and with more persistence than historically reported.
This research underscores the significant challenge of managing hairloss after cancertreatment and explores the need to evaluate new topical strategies to promote faster and higher-quality hair regrowth, as existing recovery processes are often slow and sometimes incomplete.
This narrative focuses on the experiences of two women with permanent chemotherapy-induced alopecia, highlighting the severe psychological and social impact along with dissatisfaction over pre-treatment information about hairloss, which they initially believed to be temporary.
OP is pausing hairlosstreatments to focus on mental health due to anxiety and side effects from RU58841. They plan to try topical finasteride and minoxidil after recovering from pneumonia.
There have been no new effective hairlosstreatments since finasteride, despite technological advancements. Current treatments include finasteride, minoxidil, and RU58841, with ongoing challenges and potential future solutions in research.
PP405 is a new hairlosstreatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.
Clascoterone 5% and PP405 are being discussed as potential future treatments for hairloss, with clascoterone nearing phase three completion and PP405 possibly taking a cosmetic route to market. Current treatments like minoxidil, finasteride, and RU58841 are mentioned as effective in slowing hairloss, but a complete cure remains elusive.
GT20029 is a new hairlosstreatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.